MRTX News and Press, Mirati Therapeutics Inc. From 08/05/21

Mirati Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Updates PR Newswire SAN DIEGO , Aug. 5, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial ...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

sefa ozel/iStock via Getty Images Mirati Therapeutics ([[MRTX]] -2.2%) is trading lower today after announcing a sales agreement with Cowen and Company, LLC for the sale of $500M of common stock at a par value of $0.001 per share. Per the terms of the agreement signed on July 02, “Cowe...

Mirati Therapeutics (MRTX) announces that the U.S. FDA has granted Breakthrough Therapy status to adagrasib for the potential treatment of patients with non-small cell lung cancer ((NSCLC)) who harbor the KRASG12C mutation following prior systemic therapy.Breakthrough Therapy is an ...

Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation PR Newswire SAN DIEGO , June 24, 2021 /PRNewswire/ -- Mirati T...

Shanghai's Zai Lab in-licensed Greater China rights to adagrasib, a KRASG12C inhibitor, from Mirati of San Diego in a $338 million agreement. Stemirna Therapeutics raised nearly $200 million to finance clinical trials and production of its messenger RNA COVID-19 vaccine candidate. ...

Mirati Therapeutics to Take Part in the 42nd Annual Goldman Sachs Global Healthcare Conference PR Newswire SAN DIEGO , June 2, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a f...

Mirati Therapeutics (MRTX) and Zai Lab (ZLAB) have entered into a collaboration and license agreement for adagrasib, a small-molecule KRASG12C inhibitor, in Greater China (mainland China, Hong Kong, Macau and Taiwan).Mirati will receive a $65M upfront p...

Zai Lab obtains the right to develop and exclusively commercialize adagrasib in mainland China, Hong Kong, Macau and Taiwan Mirati to receive an upfront payment of $65 million, up to approximately $273 million in potential milestone payments and high-teen- to low-twenties-percent ...

Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China - Zai Lab obtains the right to develop and exclusively commercialize adagrasib in China, Hong Kong, Macau and Taiwan - Mirati to receive an upfront payment of $...